Gut microbiota analyses of cutaneous T-cell lymphoma patients undergoing narrowband ultraviolet B therapy reveal alterations associated with disease treatment

被引:1
|
作者
Nguyen, William Q. [1 ]
Chrisman, Lauren P. [1 ]
Enriquez, Gail L. [2 ]
Hooper, Madeline J. [1 ]
Griffin, Teresa L. [1 ]
Ahmad, Merjaan [2 ]
Rahman, Sophia [2 ]
Green, Stefan J. [3 ]
Seed, Patrick C. [4 ,5 ]
Guitart, Joan [1 ]
Burns, Michael B. [2 ]
Zhou, Xiaolong A. [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA
[2] Loyola Univ Chicago, Dept Biol, Chicago, IL USA
[3] Rush Univ, Genom & Microbiome Core Facil, Med Ctr, Chicago, IL USA
[4] Ann & Robert H Lurie Childrens Hosp Chicago, Div Pediat Infect Dis, Chicago, IL USA
[5] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL USA
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 14卷
关键词
cutaneous T cell lymphoma; microbiome; phototherapy; gut dysbiosis; cancer; lymphoma; skin cancer; inositol; MYCOSIS-FUNGOIDES; SKIN MICROBIOME; PATHOGENESIS; DIVERSITY; BACTERIA; PROTEINS; BUTYRATE; 16S;
D O I
10.3389/fimmu.2023.1280205
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recent studies have shown a close relationship between cutaneous T-cell lymphoma (CTCL) and its microbiome. CTCL disease progression is associated with gut dysbiosis and alterations in bacterial taxa parallel those observed in immunologically similar atopic dermatitis. Moreover, the microbial profile of lesional skin may predict response to narrowband ultraviolet B (nbUVB), a common skin-directed therapy. However, the relationship between the gut microbiome, an immunologically vital niche, and nbUVB remains unexplored in CTCL. Herein, we performed 16S rRNA sequencing and PICRUSt2 predictive metagenomics on DNA extracted from stool swabs of 13 CTCL patients treated with nbUVB, 8 non-treated patients, and 13 healthy controls. Disease response was assessed with modified Severity Weighted Assessment Tool (mSWAT); of nbUVB-treated patients, 6 improved (decreased mSWAT), 2 remained stable, and 5 worsened (increased mSWAT). Protective commensal bacteria including Lactobacillaceae and Erysipelatoclostridiaceae were significantly less abundant in CTCL patients compared to controls. With treatment, the CTCL gut microbiome exhibited decreased phylogenetic diversity and lower relative abundance of pro-inflammatory Sutterellaceae. Sutterellaceae was also significantly more abundant in patients who worsened, and Eggerthellaceae and Erysipelotrichaceae trended higher in patients who improved. Finally, PICRUSt2 functional predictions based on shifts in abundance of bacterial sequences repeatedly identified alterations in inositol degradation, which plays a key role in host immunomodulation, including inositol phospholipid signaling relevant to T-cell survival and proliferation. Our results bolster the paradigm of gut dysbiosis in CTCL and its functional implications in disease pathogenesis, and further delineate bacterial taxa associated with nbUVB response and with nbUVB treatment itself.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] EXTRACORPOREAL PHOTOPHERESIS FOR THE TREATMENT OF 34 PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)
    KOH, HK
    DAVIS, BE
    MEOLA, T
    LIM, HW
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (04) : 567 - 567
  • [42] The Role of Histone Deacetylase Inhibitors in the Treatment of Patients With Cutaneous T-Cell Lymphoma
    Hymes, Kenneth B.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (02): : 98 - 109
  • [43] Treatment of 22 patients with cutaneous T-cell lymphoma with extracorporeal photopheresis.
    Camisa, C
    Panzarella, K
    Tuason, L
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 108 (04) : 822 - 822
  • [44] Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: Experience in 44 patients
    Zinzani, PL
    Baliva, G
    Magagnoli, M
    Bendandi, M
    Modugno, G
    Gherlinzoni, F
    Orcioni, GF
    Ascani, S
    Simoni, R
    Pileri, SA
    Tura, S
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (13) : 2603 - 2606
  • [45] Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy
    Wollina, U
    Liebold, K
    Kaatz, M
    Looks, A
    Stuhlert, A
    Lange, D
    ONCOLOGY REPORTS, 2000, 7 (06) : 1197 - 1201
  • [46] Composite lymphomas - unusual presentation of a cutaneous T-cell lymphoma under B-cell lymphoma treatment
    Hoffmann, F.
    Heine, A.
    Wenzel, J.
    Froehlich, A.
    Landsberg, J.
    Sirokay, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 43 - 44
  • [47] Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
    Voltin, Conrad-Amadeus
    Godel, Philipp
    Beckmann, Laura
    Heger, Jan-Michel
    Kobe, Carsten
    Kutsch, Nadine
    Borchmann, Peter
    Dietlein, Markus
    Herrmann, Ken
    Stelljes, Matthias
    Rahbar, Kambiz
    Lenz, Georg
    Reinhardt, H. Christian
    Teichert, Marcel
    Noppeney, Richard
    Albring, Jorn C.
    Seifert, Robert
    von Tresckow, Bastian
    Flossdorf, Sarah
    Hanoun, Christine
    HEMASPHERE, 2023, 7 (01): : E817
  • [48] Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma
    Coors, EA
    von den Driesch, P
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : 363 - 367
  • [49] Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma
    Leman, JA
    Dick, DC
    Morton, CA
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2002, 27 (06) : 516 - 518
  • [50] Treatment of indolent cutaneous T-cell lymphoma with hypofractionated radiation therapy in three cats
    Chadsey, Laura E.
    Cook, Matthew R.
    Green, Eric E.
    Jennings, Ryan N.
    Moore, Peter F.
    Vernau, William
    Kisseberth, William C.
    Diaz, Sandra F.
    VETERINARY DERMATOLOGY, 2021, 32 (05) : 515 - e143